Identification

Name
Bopindolol
Accession Number
DB08807
Type
Small Molecule
Groups
Approved
Description

Bopindolol (INN) is a beta blocker. It is an ester which acts as a prodrug for "pindolol":http://drugbank.ca/drugs/DB00960.

Structure
Thumb
Synonyms
  • Sandonorm
International/Other Brands
Sandonorm
Categories
UNII
KT304VZO57
CAS number
62658-63-3
Weight
Average: 380.48
Monoisotopic: 380.209992772
Chemical Formula
C23H28N2O3
InChI Key
UUOJIACWOAYWEZ-UHFFFAOYSA-N
InChI
InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
IUPAC Name
1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate
SMILES
CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1

Pharmacology

Indication

For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.

Structured Indications
Not Available
Pharmacodynamics

Bopindolol is a prodrug of pindolol. Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Mechanism of action

Bopindolol (as pindolol) non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.

TargetActionsOrganism
ABeta-1 adrenergic receptor
partial agonist
Human
UBeta-2 adrenergic receptor
partial agonist
Human
U5-hydroxytryptamine receptor 1ANot AvailableHuman
U5-hydroxytryptamine receptor 1BNot AvailableHuman
UBeta-3 adrenergic receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bopindolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bopindolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Bopindolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bopindolol.Approved
AcetohexamideBopindolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Acetylcholine.Approved
AcetyldigitoxinBopindolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBopindolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bopindolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Experimental, Investigational
AlaproclateThe serum concentration of Bopindolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Bopindolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Bopindolol.Approved, Illicit
AlfuzosinBopindolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Bopindolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Bopindolol.Approved
Ambroxol acefyllinateBopindolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AminophyllineBopindolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bopindolol.Approved, Investigational
AmobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bopindolol can be decreased when combined with Amodiaquine.Approved, Investigational
AndrographolideAndrographolide may decrease the antihypertensive activities of Bopindolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Bopindolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bopindolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Bopindolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
ArbutamineBopindolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Arecoline.Experimental
ArformoterolBopindolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bopindolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bopindolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
BambuterolBopindolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneThe serum concentration of Bopindolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Barbital.Illicit
BendazacBendazac may decrease the antihypertensive activities of Bopindolol.Experimental
BenorilateBenorilate may decrease the antihypertensive activities of Bopindolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bopindolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Illicit
BethanecholThe risk or severity of adverse effects can be increased when Bopindolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Bopindolol.Experimental
BL-1020BL-1020 may increase the hypotensive activities of Bopindolol.Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bopindolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bopindolol.Investigational
BucindololBopindolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Bopindolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Bopindolol.Experimental
BunazosinBopindolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bopindolol.Approved, Investigational
CabergolineBopindolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bopindolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Bopindolol.Experimental, Investigational
CarbutamideBopindolol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved, Withdrawn
CarvedilolBopindolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bopindolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
CeliprololBopindolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bopindolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Bopindolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
ChlorpropamideBopindolol may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Bopindolol.Approved
ClenbuterolBopindolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bopindolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Bopindolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bopindolol.Investigational
CymarinBopindolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bopindolol.Investigational
DapoxetineThe serum concentration of Bopindolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Bopindolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Bopindolol.Approved
DeslanosideBopindolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bopindolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bopindolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Bopindolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Bopindolol.Approved
DigitoxinBopindolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinBopindolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Bopindolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bopindolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bopindolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Bopindolol.Experimental
DobutamineBopindolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Bopindolol.Approved
DoxazosinBopindolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Bopindolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bopindolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
DuloxetineThe serum concentration of Bopindolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bopindolol.Investigational
DyphyllineBopindolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Bopindolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bopindolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bopindolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bopindolol.Approved
Ergoloid mesylateBopindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBopindolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Bopindolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Bopindolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
EtoperidoneThe serum concentration of Bopindolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Bopindolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Bopindolol.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Bopindolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bopindolol.Approved
FenoterolBopindolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Bopindolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bopindolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Bopindolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Bopindolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Bopindolol.Experimental
FingolimodBopindolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bopindolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Bopindolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Bopindolol.Experimental
FluoxetineThe serum concentration of Bopindolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bopindolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
FormoterolBopindolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Bopindolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bopindolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bopindolol.Approved, Investigational, Nutraceutical
GitoformateBopindolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBopindolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBopindolol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideBopindolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBopindolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBopindolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideBopindolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bopindolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Bopindolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
HexobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bopindolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bopindolol.Investigational
HydroxychloroquineThe metabolism of Bopindolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bopindolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bopindolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bopindolol.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Bopindolol.Experimental
IndacaterolBopindolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Bopindolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Bopindolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bopindolol.Withdrawn
IndoraminBopindolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBopindolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Bopindolol.Experimental
IsoetarineBopindolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bopindolol.Approved, Investigational, Withdrawn
IsoprenalineBopindolol may decrease the bronchodilatory activities of Isoprenaline.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Bopindolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Bopindolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bopindolol.Approved
LabetalolBopindolol may increase the orthostatic hypotensive activities of Labetalol.Approved
Lanatoside CBopindolol may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
LevomilnacipranThe serum concentration of Bopindolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
LevosalbutamolBopindolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bopindolol.Approved, Vet Approved
LisofyllineLisofylline may decrease the antihypertensive activities of Bopindolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Bopindolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bopindolol.Approved
MalathionMalathion may increase the bradycardic activities of Bopindolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bopindolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bopindolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bopindolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bopindolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bopindolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bopindolol.Approved, Investigational
MetahexamideBopindolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Bopindolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bopindolol.Investigational
MethohexitalThe serum concentration of Bopindolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bopindolol.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Bopindolol.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bopindolol.Approved, Investigational
MethylergometrineBopindolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinBopindolol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Bopindolol.Approved, Investigational
MidodrineBopindolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bopindolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bopindolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Bopindolol.Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Bopindolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Bopindolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bopindolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bopindolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bopindolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
NefazodoneThe serum concentration of Bopindolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bopindolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bopindolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Bopindolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Bopindolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bopindolol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Bopindolol.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bopindolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
OleandrinBopindolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlodaterolBopindolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bopindolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bopindolol.Approved
OrciprenalineBopindolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bopindolol.Vet Approved
OuabainBopindolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bopindolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bopindolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Bopindolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Bopindolol.Approved
ParoxetineThe serum concentration of Bopindolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Bopindolol.Investigational
PentobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Bopindolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Bopindolol.Approved
PeruvosideBopindolol may increase the bradycardic activities of Peruvoside.Experimental
PhenobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bopindolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
PirbuterolBopindolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Bopindolol.Experimental
PranoprofenPranoprofen may decrease the antihypertensive activities of Bopindolol.Experimental, Investigational
PrazosinBopindolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bopindolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bopindolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaterolBopindolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Bopindolol.Experimental
PromazinePromazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bopindolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
PropafenoneThe serum concentration of Bopindolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bopindolol.Vet Approved
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Bopindolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Bopindolol.Experimental
ProscillaridinBopindolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bopindolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bopindolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bopindolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bopindolol.Approved
ReserpineReserpine may increase the hypotensive activities of Bopindolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Bopindolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Bopindolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bopindolol can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
RitodrineBopindolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Bopindolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bopindolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
SalbutamolBopindolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bopindolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
SalmeterolBopindolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bopindolol.Approved
SecobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Bopindolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Bopindolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Bopindolol.Investigational
SertralineThe serum concentration of Bopindolol can be increased when it is combined with Sertraline.Approved
SilodosinBopindolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bopindolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bopindolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bopindolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bopindolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bopindolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Bopindolol.Experimental
TacrineTacrine may increase the bradycardic activities of Bopindolol.Investigational, Withdrawn
TamsulosinBopindolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Bopindolol.Investigational
TenidapTenidap may decrease the antihypertensive activities of Bopindolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Bopindolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bopindolol.Vet Approved
TerazosinBopindolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineBopindolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bopindolol.Approved
TheophyllineBopindolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Bopindolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Bopindolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bopindolol.Withdrawn
ThiopentalThe serum concentration of Bopindolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Bopindolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bopindolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bopindolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
TolazamideBopindolol may increase the hypoglycemic activities of Tolazamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bopindolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bopindolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Bopindolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Bopindolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bopindolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
TrimazosinBopindolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TriptolideTriptolide may decrease the antihypertensive activities of Bopindolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Bopindolol.Approved
UrapidilBopindolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bopindolol.Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bopindolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bopindolol.Approved
VilanterolBopindolol may decrease the bronchodilatory activities of Vilanterol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Bopindolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bopindolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Bopindolol.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15696
KEGG Drug
D07537
PubChem Compound
44112
PubChem Substance
99445277
ChemSpider
40146
ChEBI
355377
ChEMBL
CHEMBL357995
PharmGKB
PA165958425
Wikipedia
Bopindolol
ATC Codes
C07CA17 — Bopindolol and other diureticsC07AA17 — Bopindolol
MSDS
Download (125 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)152–153 [malonate salt]MSDS
water solubility3.3 mg/ml (malonate salt)Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0016 mg/mLALOGPS
logP4.45ALOGPS
logP4.67ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)16.8ChemAxon
pKa (Strongest Basic)9.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.35 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity111.07 m3·mol-1ChemAxon
Polarizability43.08 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7031
Caco-2 permeable+0.5503
P-glycoprotein substrateSubstrate0.6988
P-glycoprotein inhibitor IInhibitor0.558
P-glycoprotein inhibitor IINon-inhibitor0.598
Renal organic cation transporterNon-inhibitor0.7224
CYP450 2C9 substrateNon-substrate0.8035
CYP450 2D6 substrateSubstrate0.5082
CYP450 3A4 substrateNon-substrate0.5144
CYP450 1A2 substrateInhibitor0.7481
CYP450 2C9 inhibitorNon-inhibitor0.6637
CYP450 2D6 inhibitorNon-inhibitor0.6918
CYP450 2C19 inhibitorInhibitor0.5217
CYP450 3A4 inhibitorNon-inhibitor0.5458
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9049
Ames testNon AMES toxic0.8135
CarcinogenicityNon-carcinogens0.9013
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7343 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9897
hERG inhibition (predictor II)Non-inhibitor0.63
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Indoles / Benzoyl derivatives / Alkyl aryl ethers / Substituted pyrroles / Heteroaromatic compounds / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Dialkylamines / Azacyclic compounds
show 3 more
Substituents
Benzoate ester / Indole / Indole or derivatives / Benzoyl / Alkyl aryl ether / Substituted pyrrole / Heteroaromatic compound / Pyrrole / Amino acid or derivatives / Carboxylic acid ester
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
indoles (CHEBI:76749)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ: Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):496-503. Epub 2003 Nov 8. [PubMed:14608456]
  3. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398]
  4. Berendsen HH, Broekkamp CL, Van Delft AM: Antagonism of 8-OH-DPAT-induced behaviour in rats. Eur J Pharmacol. 1990 Oct 2;187(1):97-103. [PubMed:2148726]
  5. Watkins DJ, Lawrence AJ, Lewis SJ, Jarrott B: Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment. J Auton Nerv Syst. 1996 Aug 27;60(1-2):12-6. [PubMed:8884690]
  6. Brodde OE, Michel MC, Wang XL, Zerkowski HR: Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion. J Hypertens Suppl. 1988 Dec;6(4):S497-500. [PubMed:2907348]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Rubenstein LA, Zauhar RJ, Lanzara RG: Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation. J Mol Graph Model. 2006 Dec;25(4):396-409. Epub 2006 Mar 30. [PubMed:16574446]
  2. Dejgaard A, Liggett SB, Christensen NJ, Cryer PE, Hilsted J: Adrenergic receptors are a fallible index of adrenergic denervation hypersensitivity. Scand J Clin Lab Invest. 1991 Dec;51(8):659-66. [PubMed:1666931]
  3. Wheeldon NM, Newnham DM, Fraser GC, McDevitt DG, Lipworth BJ: The effect of pindolol on creatine kinase is not due to beta 2-adrenoceptor partial agonist activity. Br J Clin Pharmacol. 1991 Jun;31(6):723-4. [PubMed:1678274]
  4. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398]
  5. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of (+/- )-, (+)- and (-)-pindolol on the rat isolated aorta. J Pharm Pharmacol. 1990 Jun;42(6):444-6. [PubMed:1979630]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C: Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology. 1999 Apr;20(4):380-5. [PubMed:10088139]
  2. Haddjeri N, de Montigny C, Blier P: Modulation of the firing activity of rat serotonin and noradrenaline neurons by (+/-)pindolol. Biol Psychiatry. 1999 May 1;45(9):1163-9. [PubMed:10331108]
  3. Gobert A, Millan MJ: Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology. 1999 Aug;21(2):268-84. [PubMed:10432475]
  4. Andree B, Thorberg SO, Halldin C, Farde L: Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl). 1999 Jun;144(3):303-5. [PubMed:10435400]
  5. Fornal CA, Martin FJ, Metzler CW, Jacobs BL: Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. J Pharmacol Exp Ther. 1999 Oct;291(1):229-38. [PubMed:10490909]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Dawson LA, Nguyen HQ: The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology. 2000 Apr 3;39(6):1044-52. [PubMed:10727715]
  2. Ariani K, Hamblin MW, Tan GL, Stratford CA, Ciaranello RD: G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes. Neurochem Res. 1989 Sep;14(9):835-43. [PubMed:2512511]
  3. Leonhardt S, Herrick-Davis K, Titeler M: Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem. 1989 Aug;53(2):465-71. [PubMed:2664084]
  4. Herrick-Davis K, Titeler M, Leonhardt S, Struble R, Price D: Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: interaction with a GTP binding protein. J Neurochem. 1988 Dec;51(6):1906-12. [PubMed:3141589]
  5. Terron JA, Lopez-Munoz FJ, Hong E, Villalon CM: 2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery. Arch Int Pharmacodyn Ther. 1994 Jan-Feb;327(1):56-68. [PubMed:7944828]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on October 20, 2010 15:16 / Updated on November 09, 2017 04:40